The Subscription Model for Nicotine: How Startups Are Reinventing Addiction as a Service

There's a new kind of nicotine company, and it doesn't look anything like the tobacco giants of the 20th century. It has a minimalist website with pastel gradients and sans-serif fonts. It sells nicotine gum, pouches, and toothpicks—never cigarettes, never tobacco. Its marketing copy doesn't mention smoking or quitting. Instead, it talks about 'focus,' 'flow,' 'energy,' and 'elevating your daily ritual.' It offers monthly subscriptions, referral discounts, and a loyalty program. It posts Instagram content featuring young, attractive, diverse people in natural light, looking productive and calm. The product is nicotine. The pitch is wellness. The business model is recurring revenue, the same model that made fortunes for Netflix, Spotify, and Dollar Shave Club. And it's raising questions that the regulatory framework for nicotine was never designed to answer.

The modern nicotine startup ecosystem emerged in the late 2010s and has accelerated dramatically. Brands like Lucy, NIIN, Rogue, and ONN declare themselves 'tobacco-free,' 'modern nicotine,' or 'nicotine for the mindful consumer.' Their products—nicotine pouches, gums, lozenges, and dissolving tablets—occupy the regulatory gray zone between FDA-approved nicotine replacement therapy (which is pharmaceutical-grade, medically indicated, and tightly regulated) and recreational nicotine products (which exist in a regulatory haze in many jurisdictions). The startups lean hard into the 'wellness' positioning that big tobacco can't credibly claim: their nicotine is 'pharmaceutical-grade,' their packaging is 'sustainable,' their brand voice is 'transparent.' They're not Philip Morris. They're not JUUL. They're something new, and they want consumers and regulators to believe that new is better.

The subscription model changes the economics of nicotine consumption in ways that are both promising and troubling. On the promising side, subscriptions provide predictable revenue that can fund better product development, more consistent quality control, and direct-to-consumer distribution that eliminates underage retail access (shipping requires age verification at delivery). On the troubling side, subscriptions are designed to maximize lifetime customer value by minimizing churn—which, for a nicotine product, means keeping users dependent for as long as possible. The same behavioral economics that make subscription models effective for razors and meal kits apply to nicotine, but with a crucial difference: the 'stickiness' of a nicotine subscription isn't just about convenience. It's about addiction. A customer who stays subscribed for five years has not been 'retained' in the conventional business sense. They've been chemically tethered.

The marketing positioning of these startups represents a decisive break from cessation. Traditional nicotine replacement products are marketed as temporary aids to achieve a nicotine-free state—the packaging emphasizes 'quit smoking,' the dosing instructions include a tapering schedule, and the regulatory status as a drug reinforces the medical framing. The new startups market nicotine as a lifestyle enhancement to be used indefinitely, like caffeine. A Lucy ad reads: 'Focus on what matters. Nicotine, reimagined.' A NIIN campaign: 'The cleaner way to nicotine.' The message is that nicotine is a tool for living better, not a problem to be solved. This positioning has obvious appeal for nicotine users who are tired of being stigmatized, and it may even attract some smokers who would be turned off by traditional cessation messaging. But it also attracts never-nicotine users who want the cognitive benefits without the stigma of smoking—and who may not fully appreciate the addiction potential of the products they're subscribing to.

The regulatory response to the nicotine subscription economy is essentially nonexistent. In the United States, the FDA has authority over 'tobacco products,' which includes products derived from tobacco-derived nicotine—a category that covers most nicotine pouches. But the FDA's premarket review pathway for these products is still evolving, and enforcement has been focused on vaping products rather than oral nicotine. The startups are operating in a space where the rules are unclear and enforcement is minimal, which is precisely the environment in which venture-backed innovation thrives and regulatory problems incubate. The comparison to the early days of e-cigarettes—when JUUL exploded before regulators could respond—is too obvious to ignore and too uncomfortable to dwell on.

The investor thesis behind nicotine startups is that the global nicotine market is enormous (over $800 billion annually, dominated by combustible cigarettes), that consumers are shifting away from combustion toward 'cleaner' delivery systems, and that brands that capture the cultural transition—as JUUL briefly did—can achieve extraordinary valuations. Some investors frame the opportunity in explicitly public-health terms: these startups are accelerating the decline of smoking by providing more appealing alternatives. Others are more candid about the underlying reality: they're betting that nicotine addiction, like sugar and social media before it, can be profitably repackaged for the wellness era. The tension between these framings—public health tool vs. addiction subscription—is unresolved and largely unexamined by the venture capital firms writing the checks.

The Silicon Valley playbook applied to nicotine contains a fundamental tension that no amount of minimalist branding can resolve. The playbook says: identify a large, inefficient market. Develop a superior product. Build a beloved brand. Acquire customers efficiently. Retain them indefinitely. Grow. The problem is that in nicotine, 'retain them indefinitely' means maintaining a chemical dependence that the customers may not fully understand they're signing up for. A Spotify subscription doesn't alter brain chemistry. A Netflix habit doesn't produce withdrawal symptoms. Nicotine is different, and applying the same growth logic to a psychoactive substance that's applied to a streaming service is either naive or cynical—and the startups operating in this space have not yet convincingly demonstrated which one they are.

The nicotine subscription economy is still in its early chapters, and its ultimate impact on public health is genuinely uncertain. In the most optimistic scenario, these startups contribute to a rapid displacement of combustible cigarettes, normalize cleaner nicotine delivery, and provide adult nicotine users with products that are both less harmful and less stigmatized than smoking—improving population health even if they maintain, rather than eliminate, nicotine dependence. In the most pessimistic scenario, they create a new generation of nicotine users who would never have smoked but are drawn in by wellness branding and subscription convenience, and the public health community, once again, finds itself responding to an epidemic it failed to prevent. The difference between those scenarios will be determined by regulation—or its absence—in the next five years. The startups are moving at venture-capital speed. The regulators are not.